PRLD

Prelude is a pre-commercial precision-oncology company: the $12.1M FY2025 'revenue' is collaboration income, not product sales, so the 25.5x P/S and -819.6% net margin are artifacts of a research-stage business, not signals to trade on. The real picture is a company that lost $99.5M and burned $56.3M in operating cash while holding just $35.3M of cash and equivalents at year-end. That is well under a year of runway at the current burn, and current liabilities more than doubled YoY (+106.7%) while stockholders' equity fell 47.8% and shares grew 14.2% — the balance sheet is being consumed and dilution is the base case unless a catalyst pays. The accumulated deficit of -$683M underscores how capital-hungry this platform has been since inception.

What keeps this from an outright 'avoid' is genuine, dated optionality in the filing. The November 2025 Incyte Option Agreement gives Incyte an exclusive option to acquire the entire JAK2V617F/MPN program for $100M up front, with up to $775M in additional milestones and single-digit royalties — up to $910M total. Against a $309M market cap, a $100M option exercise alone would nearly triple the cash balance and validate the lead asset via a top-tier MPN player. Lead candidate PRT12396 received FDA IND clearance in February 2026 with a Phase 1 in high-risk PV/MF slated to begin Q2 2026, and a KAT6A degrader IND is targeted for mid-2026 — so there is a concrete near-term news cadence.